CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	3/16/2009 11:04:45 AM
	Read Replies (1) of 411

Astellas Pharma of Japan said on Monday that it was withdrawing its hostile bid for CV Therapeutics, clearing the way for the American biotech company to merge with Gilead Sciences. Astellas will cancel a tender offer of $16 a share for CV and plans to withdraw a lawsuit against the company filed in Delaware’s Court of Chancery. In a statement, the company said that it “does not see value” for its shareholders by trying to match Gilead’s bid of $20 a share.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next